Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Traveler S Diarrhea Pipeline Insight

DelveInsight’s, “Traveler’s Diarrhea - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Traveler’s Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Traveler’s Diarrhea Understanding

Traveler’s Diarrhea: Overview

Traveler’s Diarrhea (TD) is a digestive tract disorder. Classic Traveler’s Diarrhea is defined as three or more loose bowel actions with at least one of the following accompanying symptoms: nausea, vomiting, abdominal cramps or pain, fever or blood in the stools. Travelers' diarrhea usually is caused by eating food contaminated with bacteria or, less commonly, with parasites or viruses. Diarrhea usually is mild, self-limited, and resolves spontaneously. The first line of treatment for Traveler’s Diarrhea will often be home remedies and over-the-counter (OTC) treatments to resolve mild cases of the illness. Anti-motility agents provide symptomatic relief and are useful therapy in TD. Antibiotics are effective in reducing the duration of diarrhea by about a day in cases caused by bacterial pathogens that are susceptible to the particular antibiotic prescribed.


"Traveler’s Diarrhea - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Traveler’s Diarrhea pipeline landscape is provided which includes the disease overview and Traveler’s Diarrhea treatment guidelines. The assessment part of the report embraces, in depth Traveler’s Diarrhea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Traveler’s Diarrhea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Traveler’s Diarrhea R&D. The therapies under development are focused on novel approaches to treat/improve Traveler’s Diarrhea.

Traveler’s Diarrhea Emerging Drugs Chapters

This segment of the Traveler’s Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Traveler’s Diarrhea Emerging Drugs


IMM 124E: Immuron

IMM-124E is a first-in class, oral polyclonal antibody therapy. The drug is in Phase III clinical studies for the treatment of Traveler’s Diarrhea in individuals traveling to endemic areas for ETEC exposure.


LMN-101: Lumen Bioscience

LMN-101 is a cocktail of neutralizing monoclonal antibody-like protein biologics designed to bind and neutralize the primary causes of Traveler’s Diarrhea: the bacterial pathogens Campylobacter jejuni and enterotoxigenic E. coli. The drug is in Phase II clinical studies for the treatment of Traveler’s Diarrhea.

Further product details are provided in the report……..

Traveler’s Diarrhea: Therapeutic Assessment

This segment of the report provides insights about the different Traveler’s Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Traveler’s Diarrhea

There are approx. 6+ key companies which are developing the therapies for Traveler’s Diarrhea. The companies which have their Traveler’s Diarrhea drug candidates in the most advanced stage, i.e. Phase II include, AzurRx.

Phases

DelveInsight’s report covers around 7+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Traveler’s Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Traveler’s Diarrhea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Traveler’s Diarrhea therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Traveler’s Diarrhea drugs.

Traveler’s Diarrhea Report Insights

  • Traveler’s Diarrhea Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Traveler’s Diarrhea Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Traveler’s Diarrhea drugs?
  • How many Traveler’s Diarrhea drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Traveler’s Diarrhea?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Traveler’s Diarrhea therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Traveler’s Diarrhea and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Traveler’s Diarrhea: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Traveler’s Diarrhea – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Traveler’s Diarrhea companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Traveler’s Diarrhea Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

IMM 124E: Immuron

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Campylobacter jejuni/Escherichia coli oral vaccine: Immuron

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

  • Comparative Analysis

Escherichia coli/Shigella oral vaccine: Eveliqure Biotechnologies

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Traveler’s Diarrhea Key Companies

Traveler’s Diarrhea Key Products

Traveler’s Diarrhea- Unmet Needs

Traveler’s Diarrhea- Market Drivers and Barriers

Traveler’s Diarrhea- Future Perspectives and Conclusion

Traveler’s Diarrhea Analyst Views

Traveler’s Diarrhea Key Companies

Appendix

List of Table

Table 1: Total Products for Traveler’s Diarrhea

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Traveler’s Diarrhea

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Nippon Shinyaku

• Immuron

• Eveliqure Biotechnologies

• Lumen Bioscience

• Scandinavian Biopharma

• Sigmoid Pharma Limited

Forward to Friend

Need A Quote